Will the Oxford Biomedica share price keep on climbing?

The Oxford Biomedica share price is surging after extending its deal with AstraZeneca. Zaven Boyrazian investigates if this momentum can continue.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Oxford Biomedica (LSE:OXB) share price reached its highest point in over a decade this month. Like many other biotech companies, the group quickly shifted its focus to help tackle the worsening pandemic. And consequently, the firm landed one of its most lucrative partnerships to date – the manufacture of AstraZeneca’s Covid-19 vaccine.

This deal seems to have been one of the primary drivers behind Oxford Biomedica’s rapidly rising share price in 2020 that helped push it from 673p to 1,000p by the end of the year. This growth has continued since, and over the last 12 months, the stock is up more than 60%. But is this momentum about to accelerate?

Guidance gets vaccinated

I’ve previously explored Oxford Biomedica and its partnership with AstraZeneca. But as a quick reminder, the company is a small biotech group that has developed a proprietary drug development platform called LentiVector. This technology is ultimately what landed it with an 18-month vaccine manufacturing deal with AstraZeneca as it significantly reduces the hefty development costs of new medicines.

The original contract was expected to generate around £50m of additional revenue for the business. However, last month, the management team made an announcement that saw the Oxford Biomedica share price jump by double-digits within a day. Following the successful production achievements so far, AstraZeneca has agreed to increase the number of vaccine batches that Oxford Biomedica must deliver in the second half of 2021. In other words, the order sizes, and therefore income, from this deal just increased.

It’s not clear as to the exact value of the income this newly reformed agreement will generate. However, revenue guidance was raised from £50m to over £100m from this contract alone. Combining this with the income being generated from the vast collection of other products being developed on LentiVector, I believe 2021 will be a transformative year for Oxford Biomedica and its share price.

The Oxford Biomedica share price has its risks

As promising as this progress is, there are still several risks that this business faces. The most prominent of which is long-term revenue generation. The deal signed with AstraZeneca has a maximum term period of three years. In other words, it may not be a sustainable source of long-term income. This is particularly troubling given how dominant this partnership has become in the overall revenue stream for Oxford Biomedica.

The cash flows generated from this deal certainly provide a large amount of capital for reinvestment. Improvements to LentiVector may, in turn, attract additional customers that can replace the eventual loss of revenue. However, whether this can be achieved before its vaccine contract expires remains to be seen.

Needless to say, if investors see a sudden decline in Oxford Biomedica’s gross income, then I think the share price could begin to experience some significant volatility. After all, it looks like a lot of the firm’s valuation is being driven by future expectations.

The Oxford Biomedica share price has its risks

The bottom line

I’ve been an investor in Oxford Biomedica for several years now. My original investment thesis surrounded the potential of the LentiVector platform. Personally, I still believe that potential remains substantial, even after the AstraZeneca contract expires. Therefore, despite the risks, I’m cautiously optimistic that the Oxford Biomedica share price will continue to climb over the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian owns shares in Oxford Biomedica. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »